Dr José Sandoval speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the latest and potentially practice-changing trials in smouldering and relapsed or refractory multiple myeloma (R/R MM).

He begins by describing the phase III E3A06 trial, which showed that lenalidomide extended progression-free survival in patients with smouldering multiple myeloma versus observation.

Dr Sandoval moves on to R/R MM and discusses the COLOMBA trial, which found that both the subcutaneous and intravenous (IV) administration of daratumumab displayed similar response rates and pharmacokinetics in patients with R/R MM. Conversely, a faster infusion time was achieved with subcutaneous daratumumab compared to IV.

He also describes the phase III ICARIA trial, which showed that the addition of isatuximab to pomalidomide and dexamethasone improved overall response and progression-free survival in patients with R/R MM.

Dr Sandoval concludes by discussing the use of CAR T cells and a bispecific T-cell engager (BiTE) against BCMA, which has shown promising results in patients with R/R MM.